Immune-Metabolic Heterogeneity Drives Prognostic Disparity in Breast Cancer: Establishment of a Novel Risk Model and Identification of the Oncogene NAT2

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: The Second Affiliated Hospital of Nanchang University
DOI: 10.5281/zenodo.18308195
Cited by: 0

Fields of Study & Subjects

Breast Cancer Treatment Studies Ferroptosis and cancer prognosis Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
20 January 2026